Teladoc Health (NYSE:TDOC) had its price target raised by analysts at Credit Suisse Group from $165.00 to $225.00 in a research report issued on Thursday, The Fly reports. The firm currently has a “neutral” rating on the health services provider’s stock. Credit Suisse Group’s price target would indicate a potential downside of 5.31% from the company’s current price.
Several other equities analysts have also recently weighed in on TDOC. Wells Fargo & Co boosted their price objective on Teladoc Health from $105.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 16th. Deutsche Bank boosted their price target on Teladoc Health from $184.00 to $238.00 and gave the company a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their price target on Teladoc Health from $194.00 to $240.00 and gave the company an “overweight” rating in a research note on Wednesday, July 15th. Royal Bank of Canada boosted their price target on Teladoc Health from $200.00 to $235.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Stephens assumed coverage on Teladoc Health in a research note on Monday, July 6th. They set an “overweight” rating and a $250.00 price target on the stock. Fifteen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $195.04.
NYSE TDOC opened at $237.63 on Thursday. Teladoc Health has a twelve month low of $54.58 and a twelve month high of $240.00. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.14 and a current ratio of 6.14. The stock has a market capitalization of $17.69 billion, a PE ratio of -185.65 and a beta of 0.44. The stock has a 50-day simple moving average of $207.13 and a 200 day simple moving average of $158.76.
Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.11). Teladoc Health had a negative return on equity of 10.23% and a negative net margin of 13.22%. The business had revenue of $241.03 million for the quarter, compared to analyst estimates of $220.49 million. During the same period in the prior year, the firm posted ($0.41) EPS. Teladoc Health’s revenue for the quarter was up 85.0% on a year-over-year basis. As a group, equities research analysts forecast that Teladoc Health will post -1.15 EPS for the current fiscal year.
In other news, SVP Andrew Turitz sold 2,778 shares of the stock in a transaction on Friday, June 19th. The stock was sold at an average price of $200.00, for a total value of $555,600.00. Following the transaction, the senior vice president now owns 6,793 shares of the company’s stock, valued at approximately $1,358,600. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jason N. Gorevic sold 40,000 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $170.26, for a total value of $6,810,400.00. Following the completion of the transaction, the chief executive officer now directly owns 711,283 shares in the company, valued at approximately $121,103,043.58. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 189,977 shares of company stock worth $36,248,032. Company insiders own 3.42% of the company’s stock.
Several hedge funds have recently bought and sold shares of TDOC. Capital World Investors lifted its stake in shares of Teladoc Health by 510.4% in the 1st quarter. Capital World Investors now owns 1,403,845 shares of the health services provider’s stock valued at $217,610,000 after purchasing an additional 1,173,845 shares during the period. First Trust Advisors LP raised its stake in Teladoc Health by 1,406.6% during the 2nd quarter. First Trust Advisors LP now owns 1,001,290 shares of the health services provider’s stock worth $191,086,000 after buying an additional 934,829 shares during the period. Norges Bank acquired a new stake in Teladoc Health during the 4th quarter worth $51,004,000. Fred Alger Management LLC raised its stake in Teladoc Health by 405.7% during the 1st quarter. Fred Alger Management LLC now owns 625,931 shares of the health services provider’s stock worth $97,026,000 after buying an additional 502,144 shares during the period. Finally, FDx Advisors Inc. raised its stake in Teladoc Health by 16,754.5% during the 1st quarter. FDx Advisors Inc. now owns 406,531 shares of the health services provider’s stock worth $575,000 after buying an additional 404,119 shares during the period. 97.14% of the stock is currently owned by institutional investors.
About Teladoc Health
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
See Also: Marijuana Stocks Investing Considerations
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.